Key result
Miglitol significantly improved postprandial endothelial dysfunction compared to baseline and control in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Why the study?
Does miglitol improve endothelial function in patients with acute coronary syndrome and new-onset postprandial hyperglycemia?
RCT (n=54)
Single-blind
Randomized
No
Does miglitol improve endothelial function in patients with acute coronary syndrome and new-onset postprandial hyperglycemia?
In patients with acute coronary syndrome and new-onset postprandial hyperglycemia, short-term treatment with miglitol significantly improves postprandial endothelial dysfunction by reducing glucose surges.
Answers are grounded in this paper and cite their sources.
Miglitol may warrant consideration for postprandial hyperglycemia in ACS to aid endothelial recovery; extends RCT evidence on alpha-glucosidase inhibitors to vascular surrogates.
BACKGROUND: Hyperglycemia, a risk factor for development of cardiovascular disease, causes endothelial dysfunction. Alpha-glucosidase inhibitors (α-GIs) improve postprandial hyperglycemia (PPHG) and may have favorable effects on associated cardiovascular disease. Effects of α-GIs in patients with acute coronary syndrome (ACS) and PPHG remain unclear; thus, we assessed the effect of α-GI miglitol on endothelial function in such patients by digital reactive hyperemia peripheral arterial tonometry (RH-PAT). METHODS: Fifty-four patients with ACS who underwent primary percutaneous coronary intervention were enrolled in the study: 36 with new-onset PPHG and 18 with normal glucose tolerance. Eighteen PPHG patients were given 50 mg of miglitol with each meal for 1 week. Endothelial function was assessed on the basis of the RH-PAT index (RHI) before and after the 1-week miglitol treatment. The other 18 PPHG patients and the 18 NGT patients were not given any anti-diabetic agent for 1 week, and endothelial function was assessed. RESULTS: Postprandial RHI decreased significantly in patients with PPHG. Miglitol improved PPHG significantly; postprandial RHI also improved (p = 0.007). Significant inverse correlation was found between the postprandial change in RHI and postprandial fasting-to-60-minutes surge in glucose (r = -0.382, p = 0.009). Moreover, the improvement in endothelial function correlated with the reduced postprandial glucose surge achieved with miglitol (r = -0.462, p = 0.001). CONCLUSIONS: Postprandial changes in glucose are related to endothelial dysfunction in ACS. Miglitol-based improvement in PPHG appears to improve endothelial function. The effect of miglitol on glucose-dependent endothelial function might improve outcomes of ACS.
No takes yet. Share an insight, caveat, or question.
Kitano et al. (2013) conducted an RCT in Acute coronary syndrome with new-onset postprandial hyperglycemia (n=54). Miglitol vs. No anti-diabetic agent was evaluated on Postprandial change in reactive hyperemia peripheral arterial tonometry index (RHI) (p=0.007). Miglitol significantly improved postprandial endothelial dysfunction compared to baseline and control in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
Synapse has enriched 10 related papers. Consider them for comparative context: